The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 350:605-607 February 5, 2004 Number 6
NextNext

Fatty Acid Metabolism in Cystic Fibrosis
Birgitta Strandvik, M.D., Ph.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Freedman, S. D.
-PubMed Citation
In 1989, when the gene locus for cystic fibrosis was identified, expectations were great for rapid progress in understanding and effectively treating the disease. It was generally believed that cystic fibrosis was a monogenic disease, which would possibly soon be treatable by gene therapy. Now, 15 years later, it has turned out that nature is much more complicated than we had predicted. For example, even though more than 1200 mutations have been identified in the cystic fibrosis transmembrane conductance regulator gene (CFTR), the search for a relation between the different phenotypes and mutations has mainly failed. Furthermore, siblings . . . [Full Text of this Article]


Source Information

From the Department of Pediatrics, Institute of the Health of Women and Children, Göteborg University, Göteborg, Sweden.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.